Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 17/20 | 0.69 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3972176 | 0.87 | EGFR (0.60) | EGFRERBB2 | |
| SCHEMBL3975407 | 0.85 | EGFR (0.73) | EGFRERBB2P4HTMHDAC1HDAC8 | |
| SCHEMBL9414188 | 0.82 | EGFR (0.74) | EGFRERBB2P4HTMHDAC1HDAC8 | |
| SCHEMBL3975862 | 0.81 | PLA2G10 (0.53) | EGFRERBB2P4HTMHDAC1HDAC8 | |
| SCHEMBL3973361 | 0.81 | EGFR (0.52) | EGFRERBB2PLA2G10PLA2G2A | |
| SCHEMBL3977341 | 0.81 | CA1 (0.48) | EGFRERBB2PLA2G10PLA2G2A | |
| SCHEMBL12489988 | 0.80 | MEN1 (0.66) | EGFRP4HTM | |
| SCHEMBL3973201 | 0.78 | PTGER3 (0.47) | EGFRERBB2 | |
| SCHEMBL3974012 | 0.78 | EGFR (0.46) | EGFRERBB2HDAC1HDAC8 | |
| SCHEMBL5931119 | 0.76 | EGFR (0.74) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569602-B2 | Furan derivatives as EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| EP-1673360-B1 | FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2008-12-17 | — | — | EP | disclosed |
| US-20080306117-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-7417068-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-08-26 | — | — | US | disclosed |
| US-20070135503-A1 | Furan derivatives as ep4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| EP-1673360-A1 | FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2006-06-28 | — | — | EP | disclosed |
| US-20050124676-A1 | EP4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2005-06-09 | — | — | US | disclosed |
| WO-2005037812-A1 | FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124676-A1 | EP4 receptor antagonists | PTGER4, PTGER3, NR4A3 | EGFR 433/4885ERBB2 854/4885P4HTM 1471/4885 |
| US-20080306117-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER3, NR4A3 | EGFR 433/4885ERBB2 854/4885P4HTM 1471/4885 |
| US-20070135503-A1 | Furan derivatives as ep4 receptor antagonists | PTGER4, PTGER3, NR4A3 | EGFR 564/4885ERBB2 1166/4885P4HTM 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.